Exhibit 99.1


                                                      COMPANY CONTACT:

                                                      Rhonda F. Rhyne, President
                                                      rrhyne@cardiodynamics.com
                                                      800-778-4825, Ext. 1013


       CardioDynamics BioZ(R) ICG Technology Featured in American College
                        of Cardiology (ACC) Audio Series

   Company's Proprietary Technology Adopted in 16% of U.S. Cardiology Offices
         and Underscores Growing ICG Acceptance and Clinical Importance


SAN DIEGO, CA--February 19, 2008--CardioDynamics (Nasdaq: CDIC), the innovator
and leader of BioZ(R) impedance cardiography (ICG) technology, today announced
that the Company's BioZ ICG technology is featured in American College of
Cardiology's ACCEL audio series.

ACCEL is the American College of Cardiology's monthly audio series distributed
to thousands of cardiologists with the latest cardiovascular news on diagnosis,
treatment, and research. This is the first time that ICG has been the subject of
an ACCEL interview. Dr. John Schroeder, Professor of Medicine, Stanford
University School of Medicine, Stanford, California, is interviewed by the
editor of ACCEL, Dr. Richard Conti and discusses ICG technology, validity, and a
number of clinical studies which highlight ICG's clinical utility in high blood
pressure shortness of breath and heart failure patients.



Michael K. Perry, CardioDynamics Chief Executive Officer, stated, "We are
extremely pleased that the American College of Cardiology would elect to
highlight ICG on its ACCEL monthly audio series and believe it validates the
widespread use of our technology in cardiology offices and its importance in the
care of cardiac patients. The interview is very favorable in our judgment, and
we hope it will help further increase awareness of ICG among cardiologists."

BioZ ICG technology is available in approximately one out of every six (16%) of
cardiology offices as well as one out of every five (20%) outpatient heart
failure clinics in the United States. Over one million patient applications are
performed annually.

John Schroeder, M.D., F.A.C.C., Professor of Medicine, Stanford University
School of Medicine, Stanford, California, stated, "As a clinician at an academic
institution, I was pleased to be interviewed on impedance cardiography and to
share insights into this important, innovative cardiac technology that assists
clinicians in the care of heart failure, shortness of breath and high blood
pressure patients. Since heart failure admissions continue to increase in the
United States, as well as overall cardiac healthcare for the elderly, this
important advancement in technology which allows outpatient assessment is a
welcome addition to the practicing physician. If we can provide enhanced data
and care for these patients in physician offices, it can help reduce costly
emergency care visits and hospitalizations."



For further information on the interview, please contact Marjorie Swingle at
mswingle@cdic.com.

About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of
an important medical technology called BioZ(R) Impedance Cardiography (ICG). The
Company develops, manufactures and markets noninvasive BioZ(R) ICG products and
medical device electrodes. The Company's BioZ(R) ICG Systems are being used by
physicians around the world to help battle the number one killer of men and
women--cardiovascular disease. Partners include GE Healthcare, Philips Medical
Systems, and Mindray. For additional information, please refer to the company's
Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this press
release contains forward-looking statements, the accuracy of which is
necessarily subject to uncertainties and risks including the Company's sole
dependence on the BioZ(R) product line, and various uncertainties characteristic
of early growth companies, as well as other risks detailed in the Company's
filings with the SEC, including its 2006 Form 10-K. The Company does not
undertake to update the disclosures contained in this press release.